skip to main content

Our Private Equity Group provides trusted counsel derived from deep industry knowledge to established as well as up-and-coming private equity firms. We represent firms of every size across the spectrum of investment strategies, and we build long-standing relationships with our clients. As active participants in the private equity industry, we are able to advise our clients on the latest innovations, as well as current market practices and trends.

Casdin Capital to Invest in Fluidigm

Paul, Weiss is advising Casdin Capital, LLC, in its $250 million investment, alongside Viking Global Investors LP, in Fluidigm Corporation. Fluidigm is a developer, manufacturer and marketer of health and disease technology intended to accelerate the development of more effective therapies for cancer, immunology and immunotherapy, among others. The investment will significantly advance Fluidigm’s organic and inorganic high-growth initiatives, optimize its cost structure, and expand its relationships with customers and other companies in the life sciences industry. The transaction is expected to close in the first quarter of 2022, subject to customary closing conditions. Upon closing of the investment, Fluidigm will change its name to Standard BioTools Inc.

The Paul, Weiss team includes, among others, corporate partners Krishna Veeraraghavan, John Kennedy and Caith Kushner, and counsel Oliver Board and David Sobel; executive compensation partner Jean McLoughlin; tax partner Robert Holo; intellectual property partner Jonathan Ashtor and counsel Michael Kurzer; litigation partners Geoffrey Chepiga and Liza Velazquez, and counsel Peter Jaffe and Rachel Fiorill; and antitrust counsel Yuni Sobel and Marta Kelly.

© 2022 Paul, Weiss, Rifkind, Wharton & Garrison LLP

Privacy Policy